RECRUITING STUDIES

Asthma

Dr. Curtis Veal is conducting a study for patients with asthma. The study evaluates the effectiveness of an investigational agent (self-administered via inhaler) in the treatment of asthma.

Principal Investigator: Curtis Veal, MD
Sub-Investigators: Linda Anderson, MD; Charles Lee, MD; Samuel Nadler, MD; Embra Roper, MD
Study Coordinator: Gary Brown, MA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Celiac Disease

Dr. Craig Pepin is conducting a study for patients with celiac disease maintained on a gluten-free diet who have experienced at least one moderate or severe symptom in the past month. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the management of celiac disease.

Principal Investigator: Craig Pepin, MD
Study Coordinator: Gary Brown, MA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Clostridium difficile infection (c-diff)

Dr. Warren Dinges is conducting a study for patients with c-diff. The study evaluates the effectiveness, safety and tolerability of an investigational agent (administered as a single infusion) in addition to standard of care (SOC) therapy in the treatment of c-diff.

Principal Investigator: Warren Dinges, MD, PhD 
Sub-Investigators: Michael Bolton, MD, Amy Treakle, MD
Study Coordinator: Michelle Harder, MA
Phone: (206) 860-5432
E-mail: research@polyclinic.com

 

Diabetes (Type 2) with Cardiovascular Disease or Risk Factors 

Dr. Michael Williams is conducting a study for patients with either established cardiovascular disease or at least two cardiovascular risk factors. The study evaluates the effectiveness of an FDA approved agent (administered once daily orally) on the incidence of cardiovascular death, myocardial infarction (heart attack) or stroke. 

Principle Investigator: Michael Williams, MD
Sub-Investigator: Ken Gross, MD
Study Coordinator: Gary Brown, MA
Phone: (206) 860-4761
E-mail: research@polyclinic.com


Diabetes (Type 2)

Dr. Ken Gross is conducting a study for type 2 diabetes patients. The study evaluates the effectiveness of an investigational agent (self-administered subcutaneously) on glycemic control in patients with type 2 diabetes.

Principle Investigator: Ken Gross, MD
Sub-Investigator: Michael Williams, MD
Study Coordinator: Kenita Davis, MA
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Dust-Mite Induced Allergies

Dr. Arvin Mokha is conducting a study for patients with dust-mite induced allergies. The study evaluates the safety and effectiveness of an investigational agent (administered orally) in controlling dust-mite induced allergic symptoms.

Principal Investigator: Arvin Mokha, MD
Sub-Investigator: Vinod Doreswamy, MD
Study Coordinator: Gary Brown, MA 
Phone: (206) 860-4761 
E-mail: research@polyclinic.com

 

Multiple Sclerosis (Relapsing)

Dr. Braden Nago is conducting a study for patients with relapsing MS. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the treatment of relapsing MS.

Principle Investigator: Braden Nago, MD
Sub-Investigators: Alex Cooper, MD; Sameer Khan, MD; Anthony Krajcer, MD; Benduan Yang, MD
Study Coordinator: Michelle Harder, MA
Phone: (206)860-5432
E-mail: research@polyclinic.com

 

Overactive Bladder 

Dr. Emily Bradley is conducting a study for patients with overactive bladder and urinary incontinence. The study evaluates the relative safety and effectiveness of Botox in achieving 100% reduction in urinary incontinence.

Principal Investigator: Emily Bradley, MD
Sub-Investigator: Van Ginger, MD, PhD
Study Coordinator: Kenita Davis, MA 
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Psoriatic Arthritis

Dr. Anthony Krajcer is conducting a study for patients with psoriatic arthritis. The study evaluates the effectiveness and safety of an investigational agent (administered subcutaneously) in treating psoriatic arthritis.

Principal Investigator: Anthony Krajcer, MD
Study Coordinator: Michelle Harder, MA
Phone: (206) 860-5432
E-mail: research@polyclinic.com

 

Warfarin Use

Dr. Christopher Cannon is conducting a study to determine if using warfarin-related pharmacogenetic information in calculating warfarin doses will change the incidence of warfarin-related clinical events when compared to warfarin doses calculated without pharmacogenetic data.

Principal Investigator: Christopher Cannon, MD
Sub-Investigator: Melissa Hull, PharmD
Study Coordinator: Victoria Saetern, MA 
Phone: (206) 320-6752 
E-mail: research@polyclinic.com